NYSEAMERICAN:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis $0.57 +0.00 (+0.48%) Closing price 05/23/2025 04:10 PM EasternExtended Trading$0.55 -0.02 (-3.46%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NBY alerts:Sign Up Key Stats Today's Range$0.55▼$0.6050-Day Range$0.47▼$0.6552-Week Range$0.36▼$6.30Volume9,619 shsAverage Volume875,700 shsMarket Capitalization$2.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More… NovaBay Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreNBY MarketRank™: NovaBay Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NovaBay Pharmaceuticals. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovaBay Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovaBay Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovaBay Pharmaceuticals has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NovaBay Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.29% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverNovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovaBay Pharmaceuticals has recently decreased by 30.12%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.29% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverNovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovaBay Pharmaceuticals has recently decreased by 30.12%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for NBY on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.Read more about NovaBay Pharmaceuticals' insider trading history. Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NBY Stock News HeadlinesNovaBay extends CEO's contract through 2025January 22, 2025 | msn.comNovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLCOctober 29, 2024 | finance.yahoo.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 24, 2025 | Porter & Company (Ad)NovaBay Pharmaceuticals receives unsolicited offer from Refresh AcquisitionsOctober 29, 2024 | msn.comNovaBay Pharmaceuticals (AMEX:NBY) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comNovaBay Pharmaceuticals (AMEX:NBY) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comWhat's Going On With NovaBay Pharmaceuticals Shares Friday?September 20, 2024 | msn.comNovaBay Pharmaceuticals, Inc. (B9P0.F)August 20, 2024 | finance.yahoo.comSee More Headlines NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed this year? NovaBay Pharmaceuticals' stock was trading at $0.58 at the beginning of the year. Since then, NBY shares have decreased by 1.8% and is now trading at $0.5697. View the best growth stocks for 2025 here. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by $0.35. The biopharmaceutical company earned $1.84 million during the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD). Company Calendar Last Earnings11/11/2021Today5/24/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:NBY CIK1389545 Webnovabay.com Phone(510) 899-8800Fax510-474-1577Employees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.9465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-79.70% Pretax Margin-79.70% Return on Equity-146.20% Return on Assets-69.63% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.25 Sales & Book Value Annual Sales$14.40 million Price / Sales0.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book0.37Miscellaneous Outstanding Shares4,210,000Free Float4,160,000Market Cap$2.40 million OptionableNot Optionable Beta2.82 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSEAMERICAN:NBY) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.